{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:39:54Z","timestamp":1788446394013,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.puhe.2023.10.036","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T07:29:18Z","timestamp":1702366158000},"page":"215-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-7105","authenticated-orcid":false,"given":"C.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-4269","authenticated-orcid":false,"given":"P.C.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.puhe.2023.10.036_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.puhe.2023.10.036_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10049","key":"10.1016\/j.puhe.2023.10.036_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.puhe.2023.10.036_bib4","author":"World Health Organization"},{"key":"10.1016\/j.puhe.2023.10.036_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.12688\/wellcomeopenres.17941.1","article-title":"Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?","volume":"7","author":"Campbell","year":"2022","journal-title":"Wellcome Open Res"},{"issue":"3","key":"10.1016\/j.puhe.2023.10.036_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/jvh.13452","article-title":"Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis","volume":"28","author":"Campbell","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.puhe.2023.10.036_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.puhe.2023.10.036_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"issue":"39","key":"10.1016\/j.puhe.2023.10.036_bib14","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.3748\/wjg.v19.i39.6515","article-title":"Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy","volume":"19","author":"Wong","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.puhe.2023.10.036_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.puhe.2023.10.036_bib16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.puhe.2023.10.036_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","article-title":"High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma","volume":"26","author":"Chan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.puhe.2023.10.036_bib18","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.puhe.2023.10.036_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MEG.0000000000001537","article-title":"Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink","volume":"32","author":"Ferreira","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.puhe.2023.10.036_bib24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.puhe.2023.10.036_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"issue":"39","key":"10.1016\/j.puhe.2023.10.036_bib26","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.3748\/wjg.v19.i39.6515","article-title":"Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy","volume":"19","author":"Wong","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.puhe.2023.10.036_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.puhe.2023.10.036_bib32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamapediatrics.2021.1685","article-title":"Association between race and COVID-19 outcomes among 2.6 million children in England","volume":"175","author":"Saatci","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"19","key":"10.1016\/j.puhe.2023.10.036_bib33","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1136\/heartjnl-2020-317393","article-title":"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people","volume":"106","author":"Hippisley-Cox","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.puhe.2023.10.036_bib34","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.puhe.2023.10.036_bib35","author":"Vinogradova"},{"key":"10.1016\/j.puhe.2023.10.036_bib36","series-title":"Flexible imputation of missing data","author":"Van Buuren","year":"2018"},{"key":"10.1016\/j.puhe.2023.10.036_bib37","volume":"vol. 1","author":"Rubin","year":"1987"},{"issue":"1","key":"10.1016\/j.puhe.2023.10.036_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10198-008-0129-y","article-title":"Can we afford to ignore missing data in cost-effectiveness analyses?","volume":"10","author":"Marshall","year":"2009","journal-title":"Eur J Health Econ"},{"issue":"8","key":"10.1016\/j.puhe.2023.10.036_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005809","article-title":"The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study","volume":"4","author":"Hippisley-Cox","year":"2014","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.puhe.2023.10.036_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cld.904","article-title":"Development of hepatocellular carcinoma in patients with suppressed viral replication: changes in risk over time","volume":"15","author":"Udompap","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"S1","key":"10.1016\/j.puhe.2023.10.036_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.14365","article-title":"Hepatitis B: who to treat? A critical review of international guidelines","volume":"40","author":"Huang","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.puhe.2023.10.036_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19407","article-title":"Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.puhe.2023.10.036_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: recent advances","volume":"26","author":"Lin","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.puhe.2023.10.036_bib46","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021436","article-title":"Hepatitis B virus genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/j.puhe.2023.10.036_bib47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.puhe.2023.10.036_bib48","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.3389\/fmicb.2020.616023","article-title":"Comprehensive analysis of clinically significant hepatitis B virus mutations in relation to genotype, subgenotype and geographic region","volume":"11","author":"Araujo","year":"2020","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.puhe.2023.10.036_bib49","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.30973","article-title":"Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"71","author":"Goh","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.puhe.2023.10.036_bib50","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/cancers12040874","article-title":"Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis","volume":"12","author":"Facciorusso","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.puhe.2023.10.036_bib51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cancers12030671","article-title":"Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"12","author":"Islam","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.puhe.2023.10.036_bib52","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","article-title":"Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study","volume":"68","author":"Kim","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.puhe.2023.10.036_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.14835","article-title":"Association between proton pump inhibitors and the risk of hepatocellular carcinoma","volume":"48","author":"Shao","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.puhe.2023.10.036_bib54","first-page":"2865","article-title":"Association between proton pump inhibitor use and risk of hepatocellular carcinoma: a Korean nationally representative cohort study","volume":"11","author":"Kim","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.puhe.2023.10.036_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12072-019-10010-3","article-title":"Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.puhe.2023.10.036_bib56","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.30247","article-title":"Proton pump inhibitors and risk of hepatocellular carcinoma in patients with chronic hepatitis B or C","volume":"69","author":"Kao","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.puhe.2023.10.036_bib57","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00228-020-02854-8","article-title":"Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis","volume":"76","author":"Song","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.puhe.2023.10.036_bib58","first-page":"1","article-title":"Cohort profile: the National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset","author":"Wang","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10.1016\/j.puhe.2023.10.036_bib59","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/liv.14334","article-title":"Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B","volume":"40","author":"Voulgaris","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.puhe.2023.10.036_bib60","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.17941.1","article-title":"Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?","volume":"7","author":"Campbell","year":"2022","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.puhe.2023.10.036_bib62","unstructured":"Cirrhosis in over 16s Assessment and management NICE guideline NG50. Available from: https:\/\/www.nice.org.uk\/guidance\/ng50."}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350623004134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350623004134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:44:30Z","timestamp":1758501870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033350623004134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"alternative-id":["S0033350623004134"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2023.10.036","relation":{},"ISSN":["0033-3506"],"issn-type":[{"value":"0033-3506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation","name":"articletitle","label":"Article Title"},{"value":"Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.puhe.2023.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of The Royal Society for Public Health.","name":"copyright","label":"Copyright"}]}}